Literature DB >> 19758369

Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant.

Karoline Krause1, Martin Metz, Torsten Zuberbier, Marcus Maurer, Markus Magerl.   

Abstract

The bradykinin B2 receptor antagonist icatibant has recently become available for treating hereditary angioedema. Our observations demonstrate icatibant to be effective and safe for the treatment of both, abdominal and cutaneous attacks in a practice setting beyond clinical studies.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19758369     DOI： 10.1111/j.1610-0387.2009.07215.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN： 1610-0379            Impact factor:   5.584


  3 in total

Review 1.  [Diagnostics and exclusion of hereditary angioedema : a standarized approach for the practice].

Authors:  M Magerl; J Brasch; U Förster; B Hauswald; E B Mohr; B Mohr; J Prässler; R Treudler; R Vetter; V Wahn; V Zampeli; V Zampelli; M Ziemer; M Maurer
Journal:  Hautarzt       Date:  2012-07       Impact factor: 0.751

2.  An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II.

Authors:  Bernard Floccard; Etienne Hautin; Laurence Bouillet; Brigitte Coppere; Bernard Allaouchiche
Journal:  Core Evid       Date:  2012-09-27

3.  Hereditary angioedema in Austria: prevalence and regional peculiarities.

Authors:  Clemens Schöffl; Michaela Wiednig; Lukas Koch; Daniel Blagojevic; Peter Duschet; Thomas Hawranek; Tamar Kinaciyan; Angela Öllinger; Werner Aberer
Journal:  J Dtsch Dermatol Ges       Date:  2019-03-18       Impact factor: 5.584
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.